Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

Interest of Denosumab Treatment in Osteoporosis Associated to Systemic Mastocytosis

Trial Profile

Interest of Denosumab Treatment in Osteoporosis Associated to Systemic Mastocytosis

Recruiting
Phase of Trial: Phase III

Latest Information Update: 25 May 2018

At a glance

  • Drugs Denosumab (Primary)
  • Indications Osteoporosis
  • Focus Therapeutic Use
  • Acronyms DenosuMast
  • Most Recent Events

    • 31 Aug 2018 Biomarkers information updated
    • 06 Mar 2018 Planned End Date changed from 30 Jan 2023 to 30 Mar 2023.
    • 06 Mar 2018 Planned primary completion date changed from 30 Jan 2021 to 30 Mar 2021.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top